This gene panel provides oncologists with clinically actionable insights from individual patients’ tumor tissue. The detailed genetic information obtained through this gene panel testing allows oncologists to make informed treatment decisions.

This gene panel includes common and rare gene fusions and identifies novel fusion partners. This aspect of the gene panel testing is particularly valuable as it expands the understanding of fusion events in cancer, potentially uncovering new therapeutic targets or diagnostic markers that were previously unknown.

This gene panel goes beyond genetic alterations by incorporating immunotherapy biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and programmed death-ligand 1 (PD-L1) expression. These biomarkers play a crucial role in predicting response to immune checkpoint inhibitors, a cancer treatment that has shown remarkable success in certain patients.

This gene panel utilizes a combined NGS approach that includes solid and liquid biopsy samples. This approach enhances the resolution of the disease genomic landscape by leveraging the strengths of each sample source.